FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | Parkinson's

Team tackles therapeutic Parkinson's vax


Investigators engaged in preclinical studies have already seen how blocking a particular protein can reduce the level of nerve damage associated with Parkinson's disease. Now researchers at the University of Texas Health Science Center at Houston want to see if that same approach can be followed to develop a therapeutic vaccine for the debilitating ailment.

"We're creating a vaccine to target a protein (alpha synuclein) that accumulates in the brains of people with Parkinson's disease," said Rowen Chang, the lead researcher on the project. "If we can slow the protein buildup, I believe we will also slow the deterioration of nerve cells tied to body movement."

Chang's team is currently working to identify the best immunogen for the vaccine, which is being tested in mice. Their work is supported by the Michael J Fox Foundation for Parkinson's Research, which has devoted millions of dollars to cutting-edge research in the field. Other investigators at UTHealth are engaged in developing new and better diagnostics for Parkison's.

- check out the full article from UT

Related Article:
Vaccine reverses Parkinson's disease in animal study

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Vaccine   Parkinson's  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.